HCPCS Level II J9299: Injection, nivolumab, 1 mg
Headline: HCPCS Level II code J9299: Unit billing for nivolumab injection, 1 mg
Lead: HCPCS Level II code J9299 designates the per-milligram injectable unit for nivolumab, a programmed death‑1 (PD‑1) immune checkpoint inhibitor used across multiple oncology indications. Accurate use of this code affects drug billing, claims processing, and national spending on cancer immunotherapy.
What this represents and why it matters: J9299 is the unit-based billing code for nivolumab at 1 mg and is used when reporting the drug product on outpatient medical claims. Given nivolumab’s widespread use in malignancies such as lung, colorectal, prostate, pancreatic cancers, and melanoma, the code is consequential for reimbursement workflows, utilization tracking, and drug cost management at scale.
Key payers covered: Analysis and references include major national commercial plans and public payers: Aetna; Blue Cross Blue Shield; Cigna Health; United Healthcare; and Medicare.
What readers will learn: The publication presents benchmarks for unit billing and utilization, payer coverage patterns, common billing considerations tied to the HCPCS Level II J9299 descriptor, and clinical context for nivolumab administration. It highlights implications for outpatient infusion services and hospital outpatient departments where systemic anticancer therapies are delivered.
Scope: National-level focus; no state-specific policy guidance is provided.
Customize your policy alerts
Sign up for hcpcs J9299 policy alerts
Get alerted when payer policies referencing J9299 are released or updated.
Monitor payer policy activity
Billing Code Overview
HCPCS Level II code J9299 denotes injection, nivolumab, 1 mg. This code represents a billed unit for the immunotherapy drug nivolumab, supplied as an injectable formulation at a per-milligram basis.
Service Type: Drug administration — systemic anticancer therapy
Typical Site of Service: Outpatient infusion center or hospital outpatient department
National Reimbursement Benchmarks
National commercial pricing centers on a BUCA average commercial rate of $149.70 for J9299, while individual commercial payers cluster at substantially lower medians. Blue Cross Blue Shield and Cigna both show medians near $32–$33, and UnitedHealth Group’s median is $34.90. Aetna displays extreme dispersion driven by outliers, with a mean far above others at $843.90 and a wide spread between its P25 ($16.50) and P75 ($34.00).
Comparing interquartile dispersion (P75 minus P25), Aetna is the widest with a range of $17.50, indicating greater variability in typical commercial payments. UnitedHealth Group and Blue Cross Blue Shield are tighter, with ranges of $4.70 and $1.20 respectively, while Cigna’s IQR is $5.80 and BUCA’s IQR is $6.70, placing them in a mid-range of dispersion.